Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.
Latest Information Update: 08 Apr 2020
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Bladder cancer; Chronic lymphocytic leukaemia; Colon cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Graft-versus-host disease; Head and neck cancer; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors Pharmacyclics Switzerland
- 06 Mar 2018 Planned End Date changed from 1 May 2020 to 2 Jul 2027.
- 06 Mar 2018 Planned primary completion date changed from 1 May 2020 to 2 Jul 2027.
- 29 Jul 2017 New trial record